The FDA issued a safety communication for laparoscopic uterine power morcellation devices used in hysterectomy and myomectomy in 2014, noting that the devices may spread uterine sarcomas and other cancerous tissue beyond the uterus. In light of the risk, the FDA recommended against the use of the devices in most women undergoing hysterectomy or myomectomy for uterine fibroids.
In the years after the notice, Advanced Surgical Concepts sought De Novo classifications for two devices intended to address the problem. The FDA classified PneumoLiner , a hysterectomy and myomectomy tissue containment system, as a Class II device and established special controls in 2016. The next year, the FDA classified a general laparoscopic power morcellation containment system, Advanced Surgical Concepts’ ContainOR, as a Class II device and again established special controls.
The availability of tissue containment systems led the FDA to update its 2014 safety communication in 2020, telling physicians they should only perform laparoscopic power morcellation for myomectomy or hysterectomy with a containment system that confines the tissue that is cut up for removal.
In the draft guidance, which is open for comment for 60 days, the FDA covers the non-clinical performance data that manufacturers of gynecologic and general tissue containment systems need to provide to meet the special controls created through the De Novo classifications. The special controls require the testing of attributes such as the impermeability of the device to tissue, cells and fluids.
The draft lists recommended test methods for all five of the special controls.
To show the impermeability of the systems, the agency is advising manufacturers to carry out material permeability testing and run integrity tests on the final finished tissue containment system. The draft features recommendations for each test, explaining, for example, that material permeability testing should use an appropriate marker, such as a viral or bacteriophage marker, that is less than or equal to the size of cancer cells.
Get the free daily newsletter read by industry experts
Even after deals already eclipsed last year's numbers, analysts predict robust activity in particular among diagnostics companies flush with cash from 2020's COVID-19 test sales.
While the guidance encouraged the use of electronic communications in recalls, a change experts have advocated for, some questioned why the agency did not address more problems with the system.
Subscribe to MedTech Dive for top news, trends & analysis
Get the free daily newsletter read by industry experts
Even after deals already eclipsed last year's numbers, analysts predict robust activity in particular among diagnostics companies flush with cash from 2020's COVID-19 test sales.
While the guidance encouraged the use of electronic communications in recalls, a change experts have advocated for, some questioned why the agency did not address more problems with the system.
The free newsletter covering the top industry headlines